अApnaFunda
Menu

ALIVUS LIFE SCIENCES LIMITED (ALIVUS)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.76 / 100
Price 79FII/DII 74
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹1,474.4 latest close · +27.4% over the last 90 sessions

₹1,200₹1,400₹1,600Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹1,200₹1,400₹1,600Jul 3Sep 4Nov 9

₹1,474.4 month-end · +64.1% over 12 months

₹1,000₹1,200₹1,400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,000₹1,200₹1,400Nov '25May '26Nov '26

₹1,474.4 month-end · +134.0% over 3 years

₹1,000₹1,500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,000₹1,500Nov '23May '25Nov '26

₹1,474.4 month-end · +113.4% since Aug '21

₹500₹1,000₹1,500Aug '21Sep '22Sep '23Oct '24Oct '25Nov '26 ₹500₹1,000₹1,500Aug '21Apr '24Nov '26

52-week range ₹819.00 to ₹1574.00 · 1-year volatility 30.4%

Was the rally earned?

+64%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 27.6x to 45.2x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: +64 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+64 ptsP/E changeShare price: +64%+64%Share priceP/E change: +64 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+64P/EShare price: +64%+64%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change+64 ptsThe P/E rose from 27.6x to 45.2x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+134%share price, 3 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 19.3x to 45.2x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: +134 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+134 ptsP/E changeShare price: +134%+134%Share priceP/E change: +134 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+134P/EShare price: +134%+134%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change+134 ptsThe P/E rose from 19.3x to 45.2x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+141%share price, 5 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 18.8x to 45.2x); per-share earnings added 0 points.
  • The share count barely moved.
P/E change: +141 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+141 ptsP/E changeShare price: +141%+141%Share priceP/E change: +141 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+141P/EShare price: +141%+141%Share price
Net profit growth0 ptsNet profit was little changed.
P/E change+141 ptsThe P/E rose from 18.8x to 45.2x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-51.0%recovered 2024-01
1-year volatility30.4%annualised
Beta vs sector index0.913-year daily, correlation 0.37
Volume spikes11last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%20222023202420252026−50.8% 0%−20%−40%202220242026−50.8%
Largest drawdowns

-51.0% (2021-08 peak to 2023-02 low, recovered 2024-01)

-34.4% (2024-09 peak to 2025-12 low, recovered 2026-08)

-22.7% (2024-02 peak to 2024-03 low, recovered 2024-07)

Most recent volume spikes

2026-11-09: 7.8x the 50-day median, price -5.4% that day

2026-11-06: 16.2x the 50-day median, price -1.1% that day

2026-11-04: 5.2x the 50-day median, price +2.7% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

45.2xP/E todayNear its historic high
Against its own history100th percentile
CheapestMedian 26.1xDearest

Usual range 13.1x to 35.0x since 2021-08.

Against Health Technology45.2x vs 37.0x
This company
45.2x
Sector median
37.0x

22% above the Health Technology median.

11.5x22.7x34.0x45.2xAug '21Sep '22Oct '23Nov '24Dec '25Nov '2611.5x22.7x34.0x45.2xAug '21May '23Feb '25Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • Revenue growth18th▼ 7 pts vs a year ago
  • EPS growth37th▼ 4 pts vs a year ago
  • P/E ↓36th▼ 23 pts vs a year ago
  • 12M momentum84th▲ 34 pts vs a year ago

Rank history

Revenue growth
EPS growth
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~28%annual earnings growth implied by the price

At a P/E of 55.5x, the price would imply about 27.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Earnings figures have not updated recently, so the company is left out of the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹1474.40
P/E
45.2x
Market Cap
₹18105 cr
Revenue (TTM)
₹1885 cr
P/S
9.6x
Promoter Holding
74.9%
12M Momentum
64.1%

52-week range

₹819.00₹1574.00
87% of the way from its 52-week low to its high

Price risk

1Y volatility
30.4%
Beta vs sector
1-year daily
0.86

Balance sheet & cash

Interest cover
operating profit ÷ interest
6.4x

Are profits backed by cash?

1 of 1checks within rangeAll clear
Other income reliance0%Within range

Other income as a share of pre-tax profit (trailing twelve months): 0.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow—Not enough data

Not enough reported data to compute this.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress—Not enough data

Not enough reported data to compute this.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, promoters trimmed 8.0 pts; DIIs added 6.5 pts; FIIs added 1.2 pts.
  • The number of shareholders fell from 2.0 lakh to 1.3 lakh (-37%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters82.8%74.9%-8.0 pts
FIIs4.4%5.5%+1.2 pts
DIIs0.6%7.2%+6.5 pts
Public and others12.1%12.4%+0.3 pts

Number of shareholders

1.3 lakhshareholders-37% since Sep '23
1.3L1.5L1.7L2.0L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 2.0 lakh
Dec '23: 1.9 lakh
Mar '24: 1.6 lakh
Jun '24: 1.5 lakh
Sep '24: 1.4 lakh
Dec '24: 1.5 lakh
Mar '25: 1.4 lakh
Jun '25: 1.4 lakh
Sep '25: 1.4 lakh
Dec '25: 1.3 lakh
Mar '26: 1.3 lakh
Jun '26: 1.3 lakh
 1.3L1.5L1.7L2.0L Sep '23Sep '24Sep '25Jun '26
Sep '23: 2.0 lakh
Dec '23: 1.9 lakh
Mar '24: 1.6 lakh
Jun '24: 1.5 lakh
Sep '24: 1.4 lakh
Dec '24: 1.5 lakh
Mar '25: 1.4 lakh
Jun '25: 1.4 lakh
Sep '25: 1.4 lakh
Dec '25: 1.3 lakh
Mar '26: 1.3 lakh
Jun '26: 1.3 lakh

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−2.1%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like ALIVUS LIFE SCIENCES LIMITED today on valuation, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −22% to +21% vs the market, against −2% for all non-financial companies in the same months.
  • The gap against the base rate (−0.6%, 80% range −8.8% to +5.5%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
HEG · Oct 2025: −57.5% vs market
NATCOPHARM · Oct 2020: −42.5% vs market
MOLDTKPAC · Jan 2023: −39.9% vs market
CCL · May 2023: −37.1% vs market
CERA · May 2023: −35.1% vs market
LTTS · Nov 2021: −33.9% vs market
JKCEMENT · Aug 2025: −31.4% vs market
ICRA · May 2020: −28.5% vs market
ALKYLAMINE · Jul 2025: −27.8% vs market
PAGEIND · Apr 2025: −24.4% vs market
TATACHEM · Feb 2020: −23.4% vs market
FLUOROCHEM · Mar 2025: −22.6% vs market
GODREJCP · May 2020: −22.4% vs market
PFIZER · Jun 2025: −22.0% vs market
CRISIL · Apr 2020: −20.6% vs market
ERIS · May 2020: −18.5% vs market
MRF · Apr 2020: −16.5% vs market
SFL · Mar 2020: −14.5% vs market
KENNAMET · Sep 2022: −14.3% vs market
NH · Jun 2025: −9.3% vs market
SRF · May 2025: −7.1% vs market
PGHL · Mar 2020: −5.0% vs market
AARTIIND · Mar 2020: −4.4% vs market
GARFIBRES · Sep 2020: −4.4% vs market
RADICO · Mar 2023: −2.7% vs market
MIDHANI · Jul 2023: −1.6% vs market
MAHSCOOTER · Apr 2025: 0% vs market
ANURAS · Jul 2025: +1.1% vs market
TECHNOE · Apr 2024: +3.1% vs market
CROMPTON · Mar 2020: +4.6% vs market
ASAHIINDIA · Aug 2025: +5.7% vs market
ASTERDM · Oct 2025: +6.2% vs market
CENTURYPLY · Oct 2021: +6.7% vs market
TIINDIA · Mar 2021: +10.2% vs market
ZYDUSLIFE · Apr 2020: +10.4% vs market
BHARATRAS · May 2020: +13.6% vs market
TEGA · May 2023: +15.2% vs market
GALAXYSURF · Jul 2020: +22.8% vs market
PHOENIXLTD · Oct 2025: +22.9% vs market
IPCALAB · Jan 2020: +23.8% vs market
TATACONSUM · Feb 2020: +29.3% vs market
FORTIS · Feb 2025: +30.3% vs market
NAVINFLUOR · Feb 2025: +40.9% vs market
GLAND · Sep 2025: +44.8% vs market
LINDEINDIA · Feb 2021: +46.8% vs market
SOLARINDS · Jun 2024: +72.0% vs market
JYOTHYLAB · Jan 2023: +80.7% vs market
BSE · Aug 2023: +81.1% vs market
CDSL · May 2020: +130.0% vs market
TATAELXSI · Jan 2020: +138.1% vs market
Similar setups −2.1%All companies −1.5%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−2.1%
All companies' median
−1.5%
Beat the market
48% vs 48%

50 past situations · 50 companies · 29 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CRISIL
Commercial Services		 Apr 2020 31x42% +2%−26% −21%
AARTIIND
Process Industries		 Mar 2020 27x18% −3%−26% −4%
PGHL
Health Technology		 Mar 2020 37x20% −2%−26% −5%
GARFIBRES
Producer Manufacturing		 Sep 2020 33x23% +80%0% −4%
NATCOPHARM
Health Technology		 Oct 2020 39x14% +53%−6% −43%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CROMPTON
Producer Manufacturing		 Mar 2020 33x39% −8%−28% +5%
TEGA
Producer Manufacturing		 May 2023 51x19% +103%0% +15%
KENNAMET
Producer Manufacturing		 Sep 2022 52x25% +99%−4% −14%
How reliable is this?

Matched on P/E, P/S, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/E and size. Not used (unavailable for this company): ROCE, operating margin and debt/equity. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ALIVUS LIFE SCIENCES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

FINE ORGANIC INDUSTRIESFINEORG
Process Industries
75%similar
market capvolatility
CAMPUS ACTIVEWEARCAMPUS
Consumer Non-Durables
67%similar
revenue growthEPS growth
3M INDIA3MINDIA
Producer Manufacturing
66%similar
promoter holdingrevenue growth
LINDE INDIALINDEINDIA
Process Industries
65%similar
volatilityEPS growth
VEDANT FASHIONSMANYAVAR
Retail Trade
64%similar
promoter holdingrevenue growth
PFIZERPFIZER
Health Technology
47%similar
revenue growthEPS growth
GLAXOSMITHKLINE PHARMACEUTICALGLAXO
Health Technology
39%similar
P/Epromoter holding
FDCFDC
Health Technology
29%similar
volatilityrevenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

27 events since Mar '22

  1. NovPriceVolume reached 16.2x its 50-day median on 2026-11-06; price -1.1% that day.
  2. AugPriceRegained the 2024-09 peak, 8 months after the low.
  3. AugPriceVolume reached 17.0x its 50-day median on 2026-08-04; price +10.0% that day.
  4. MayValuationP/E crossed above the 90th percentile of its own history to date (32.4x).
  5. DecPriceFell 34% from the Sep 2024 peak to the Dec 2025 low.
  6. DecPriceVolume reached 14.8x its 50-day median on 2025-12-04; price -0.2% that day.
  7. SepPriceVolume reached 56.4x its 50-day median on 2025-09-19; price +10.6% that day.
  8. MarValuationP/E crossed above the 90th percentile of its own history to date (33.2x).
Show 19 earlier events
  1. JanPriceVolume reached 8.4x its 50-day median on 2025-01-21; price +4.1% that day.
  2. DecPromoterPromoter holding fell 7.8 pts to 75.0%.
  3. DecInstitutionsFII + DII holding rose 5.6 pts over 1 quarter to 12.0%.
  4. DecPriceVolume reached 6.8x its 50-day median on 2024-12-11; price +1.0% that day.
  5. JulPriceVolume reached 19.5x its 50-day median on 2024-07-12; price +0.7% that day.
  6. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  7. AprPriceVolume reached 6.5x its 50-day median on 2024-04-25; price -9.2% that day.
  8. JanPriceRegained the 2021-08 peak, 11 months after the low.
  9. JanPriceVolume reached 16.8x its 50-day median on 2024-01-02; price +9.0% that day.
  10. DecValuationP/E crossed above the 90th percentile of its own history to date (20.1x).
  11. OctPriceVolume reached 5.9x its 50-day median on 2023-10-16; price +2.7% that day.
  12. SepPriceVolume reached 8.8x its 50-day median on 2023-09-22; price +3.0% that day.
  13. AprPriceVolume reached 14.8x its 50-day median on 2023-04-28; price +5.2% that day.
  14. MarPriceVolume reached 10.4x its 50-day median on 2023-03-15; price +2.0% that day.
  15. FebPriceFell 51% from the Aug 2021 peak to the Feb 2023 low.
  16. OctPriceVolume reached 19.1x its 50-day median on 2022-10-10; price +1.7% that day.
  17. AugPriceVolume reached 5.3x its 50-day median on 2022-08-01; price +2.2% that day.
  18. AprPriceVolume reached 11.5x its 50-day median on 2022-04-05; price +5.4% that day.
  19. MarPriceVolume reached 7.0x its 50-day median on 2022-03-11; price +4.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history64 months · 2021-08 to 2026-11
MonthP/ERevenue (TTM)
2026-1145.2x₹1885 cr
2026-1043.4x₹1885 cr
2026-0942.3x₹1885 cr
2026-0843.1x₹1885 cr
2026-0735.6x₹1885 cr
2026-0635.5x₹1885 cr
2026-0532.4x₹1885 cr
2026-0431.8x₹1885 cr
2026-0329.8x₹1885 cr
2026-0228.0x₹1885 cr
2026-0129.5x₹1885 cr
2025-1228.1x₹1885 cr
2025-1127.6x₹1885 cr
2025-1027.7x₹1885 cr
2025-0928.5x₹1885 cr
2025-0829.0x₹1885 cr
2025-0731.6x₹1885 cr
2025-0630.8x₹1885 cr
2025-0531.9x₹1885 cr
2025-0433.9x₹1885 cr
2025-0333.2x₹1885 cr
2025-0227.1x₹1885 cr
2025-0136.8x₹1885 cr
2024-1230.2x₹1885 cr
2024-1133.2x₹1885 cr
2024-1032.4x₹1885 cr
2024-0932.4x₹1885 cr
2024-0832.3x₹1885 cr
2024-0727.2x₹1885 cr
2024-0626.6x₹1885 cr
2024-0525.6x₹1885 cr
2024-0425.4x₹1885 cr
2024-0323.8x₹1885 cr
2024-0226.6x₹1885 cr
2024-0126.8x₹1885 cr
2023-1220.1x₹1885 cr
2023-1119.3x₹1885 cr
2023-1019.2x₹1885 cr
2023-0918.9x₹1885 cr
2023-0819.5x₹1885 cr
2023-0720.6x₹1885 cr
2023-0617.5x₹1885 cr
2023-0516.6x₹1885 cr
2023-0415.5x₹1885 cr
2023-0312.0x₹1885 cr
2023-0211.5x₹1885 cr
2023-0111.9x₹1885 cr
2022-1212.9x₹1885 cr
2022-1113.1x₹1885 cr
2022-1013.0x₹1885 cr
2022-0911.8x₹1885 cr
2022-0813.5x₹1885 cr
2022-0714.2x₹1885 cr
2022-0613.6x₹1885 cr
2022-0513.0x₹1885 cr
2022-0414.6x₹1885 cr
2022-0314.1x₹1885 cr
2022-0214.0x₹1885 cr
2022-0117.6x₹1885 cr
2021-1219.4x₹1885 cr
2021-1118.8x₹1885 cr
2021-1019.4x₹1885 cr
2021-0920.9x₹1885 cr
2021-0821.2x₹1885 cr

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback